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Tumor necrosis factor (TNF) ligand and receptor su-
perfamily members play critical roles in diverse devel-
opmental and pathological settings. In search for novel
TNF superfamily members, we identified a murine chro-
mosomal locus that contains three new TNF receptor-
related genes. Sequence alignments suggest that the li-
gand binding regions of these murine TNF receptor
homologues, mTNFRH1, -2 and -3, are most homologous
to those of the tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) receptors. By using a number
of in vitro ligand-receptor binding assays, we demon-
strate that mTNFRH1 and -2, but not mTNFRH3, bind
murine TRAIL, suggesting that they are indeed TRAIL
receptors. This notion is further supported by our dem-
onstration that both mTNFRH1:Fc and mTNFRH2:Fc fu-
sion proteins inhibited mTRAIL-induced apoptosis of
Jurkat cells. Unlike the only other known murine TRAIL
receptor mTRAILR2, however, neither mTNFRH2 nor
mTNFRH3 has a cytoplasmic region containing the well
characterized death domain motif. Coupled with our
observation that overexpression of mTNFRH1 and -2 in
293T cells neither induces apoptosis nor triggers NFB
activation, we propose that the mTnfrh1 and mTnfrh2
genes encode the first described murine decoy receptors
for TRAIL, and we renamed them mDcTrailr1 and -r2,
respectively. Interestingly, the overall sequence struc-
tures of mDcTRAILR1 and -R2 are quite distinct from
those of the known human decoy TRAIL receptors, sug-
gesting that the presence of TRAIL decoy receptors rep-
resents a more recent evolutionary event.
In many biological systems, cellular outcomes are often de-
termined by environmental cues delivered through ligand and
receptor interactions on the cell surface. One group of ligand/
receptor pairings critical to this decision-making process is the
tumor necrosis factor (TNF)1 ligand and receptor superfamily
(1). Upon ligand engagement, TNF receptors trigger intracel-
lular signaling pathways that lead to cell proliferation, differ-
entiation, or apoptosis. The pivotal roles of these TNF ligands
and receptors across diverse biological areas are perhaps best
illustrated by gene knockout studies demonstrating the essen-
tial involvement of the lymphotoxin pathway in lymphoorga-
nogenesis (2, 3), the BAFF pathway in B-cell development (4),
the RANKL pathway in osteoclastogenesis (5), and the EDA
pathway in hair-follicle formation (6). The ability of many
members of this family to regulate both innate and adaptive
immunity also makes them attractive targets for therapeutic
intervention of various immune disorders, as exemplified by
the success of anti-TNF therapy in treating rheumatoid arthri-
tis and Crohn’s disease (7).
TNF receptor family members are characterized by the pres-
ence of cysteine-rich repeats (CRDs) in their extracellular do-
mains (8, 9). A CRD typically contains two structural motifs,
called modules, that are stabilized by disulfide bridges formed
between the cysteine residues. The linear arrangement of mod-
ules creates a scaffold that supports the unusual elongated
structures seen in all known crystal structures of TNFR family
members. In contrast to the absolute conservation of CRDs, the
signaling potentials of TNF receptors vary a great deal.
Whereas most TNF receptors, such as TNFR1, CD40, and Fas,
have cytoplasmic domains containing well characterized sig-
naling motifs such as TRAF-binding sites and/or death domain
(10, 11), others lack signaling capacity. These non-signaling
receptors include soluble receptors OPG and DcR3, the GPI-
anchored human TRAILR3, and human TRAILR4 that con-
tains a defective signaling cytoplasmic tail. The biological func-
tion of these so-called “decoy receptors” is likely to antagonize
the pairing between ligands and their signaling receptor coun-
terparts, providing a critical mechanism for ligand desensiti-
zation (12–15).
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Whereas many members of the TNF ligand superfamily dem-
onstrate one-to-one pairing with their cognate receptors, others
exhibit complex ligand/receptor cross-talks (8). In particular,
the TNF ligand TRAIL has five receptors in human, at least
based on in vitro binding assays (16, 17). Among the hTRAIL
receptors, hTRAILR1 and -R2 each contain a death domain in
the cytoplasmic region, and as a result hTRAIL can efficiently
induce caspase-dependent apoptosis in cell lines expressing
these receptors (18, 19). As mentioned before, hTRAILR3 and
-R4 are both considered decoy receptors, but their in vivo func-
tion is not clear. The fifth TRAIL-binding TNF receptor is OPG,
which also binds to RANKL (17). Whereas studies of OPG
knockout mice have clearly demonstrated OPG as a decoy
receptor for RANKL, the in vivo relevance of OPG to TRAIL
biology remains to be established (17, 20). Interestingly, only
one murine TRAIL receptor, mTRAILR2/mKiller, has been
identified so far (21). Similar to hTRAILR1 and -R2,
mTRAILR2 contains a death domain motif and induces apo-
ptosis when overexpressed or engaged by TRAIL.
Known as the TNF receptor “signature,” the uniquely spaced
cysteine residues found in these receptors allows identification
of potential new family members from unprocessed genomic
sequences by bioinformatic means. In this study, we describe
the identification through genome mining of three new TNFR
family members closely clustered on mouse chromosome 7. All
three genes, named mTNFRH1, -2 and -3, encode proteins
containing classic TNF receptor-like CRDs. We also demon-
strate that, whereas mTNFRH3 remains an orphan receptor,
mTNFRH1 and two splice variants of mTNFRH2 can specifi-
cally bind murine TRAIL, but not the closely related RANKL
nor any other ligand we have tested. Both sequence analysis
and transient overexpression studies, however, suggest that
mTNFRH1 and -2 are not signaling TRAIL receptors but
rather the previously unknown murine TRAIL “decoy” recep-
tors. Given their low overall sequence homology to hTRAILR3
and hTRAILR4, we propose that mTNFRH1 and -2 belong to a
new class of TRAIL decoy receptors and thus named them
mDcTRAILR1 and -R2, respectively. The identification of these
two murine TRAIL decoy receptors will likely facilitate our
understanding of the complex biology underlying TRAIL li-
gand/receptor interactions through the generation of mice de-
ficient in these receptors.
EXPERIMENTAL PROCEDURES
Reagents—Anti-FLAG M2 monoclonal antibody, M2-agarose, and
Biot-M2 were purchased from Sigma. PI-PLC from Bacillus thuringien-
sis was purchased from ICN Biochemicals (Aurora, OH). hTRAIL,
hRANKL, hEDA, hTRAILR1:Fc, hTRAILR2:Fc, hTRAILR3:Fc,
hTRAILR4:Fc, hOPG, and hEDAR:Fc were from Apotech (www.
apotech.com). muOPG:Fc was purchased from R & D Systems (www.
rndsystems.com). Cell culture reagents were from Invitrogen.
Cell Lines—293T cells were grown in DMEM supplemented with
10% heat-inactivated fetal calf serum (FCS). Jurkat cells were main-
tained in RPMI  10% FCS and HEK-293 cells in DMEM:F12  2%
FCS. All media contained 10 g/ml each penicillin and streptomycin.
All the cell lines used for Northern analysis were purchased from ATCC
and grown in recommended culture media.
Transient transfections in 293T cells for the production of soluble
proteins in serum-free Opti-MEM and establishment of stable transfec-
tants in HEK-293 cells were performed as described previously (22).
Identification and Cloning of mDcTRAILR-1, mDcTRAILR-2 and
mTNFRH-3 cDNAs—The cDNA of mTNFRH1/mDcTRAILR1 was ob-
tained from EST clones (GenBankTM accession numbers AI156311,
AI747041, and BG077775). A full-length coding cDNA was generated
from these clones by a PCR-based method and cloned into the PCR-3
mammalian expression vector (Invitrogen).
The full-length cDNA clone of mTNFRH3 was obtained by screening
a mouse spleen phage cDNA library (Stratagene) using a partial cDNA
probe amplified from the E14 ES cell line. The screening was performed
according to recommended protocol from Stratagene and resulted in one
cDNA clone from about 1  106 independent clones.
The cDNAs of both splicing variants of mTNFRH2/mDcTRAILR2
were obtained by RT-PCR using primer sequences designed on genomic
sequences. Briefly, total RNA was isolated from NIH3T3 cells using
TRIzol (Invitrogen) followed by first strand synthesis using Superscript
II (Invitrogen). PCR was performed using the Touchdown protocol. The
cDNA of mTRAILR2/mKiller was obtained similarly using RNA from
the J1 ES cell line.
Expression Vector—The PCR-3 mammalian expression vectors en-
coding the various FLAG ligand and receptor:Fc fusion proteins were
generated as described (22), using cDNA sequences encoding the fol-
lowing amino acid residues: mDcTRAILR1 (aa 1–158), mDcTRAILR2L
(aa 1–171), mDcTRAILR2S (aa 1–180), mTNFRH3 (aa 1–162),
muTRAILR2 (aa 1–177), muRANK (aa 1–200), muTRAIL (aa 120–291),
and muRANKL (aa 157–316).
Northern Analysis—Tissue expression patterns were done using pre-
made Northern blots from Ambion. For expression patterns in various
murine cell lines, total RNA was isolated using TRIzol reagent (Invitro-
gen), and 20 g of total RNA was loaded for each lane. Probes for each
gene were generated using PCR amplification of the coding regions and
labeled with [-32P]dCTP using Ready-To-Go DNA labeling beads (Am-
ersham Biosciences). Blots were hybridized and washed in ExpressHyb
solution (Clontech) according to the manufacturer’s protocol.
Coimmunoprecipitation and ELISA—Receptors:Fc (500 ng) mixed
with FLAG ligands (200 ng) in 1 ml of PBS were incubated for 2 h at
4 °C on a wheel with 2.5 l of protein A-Sepharose (Amersham Bio-
sciences). Beads were harvested, loaded in empty mini-columns,
washed 3 with 100 volumes of PBS, eluted with 15 l of 0.1 M citrate
NaOH, pH 2.7, neutralized, and analyzed by Western blotting with
anti-FLAG M2 antibody. Membranes were subsequently reprobed with
goat anti-human IgG antibodies.
The interaction between receptor:Fc and FLAG ligands by ELISA
was performed as described previously (23). Briefly, ELISA plates were
coated with mouse anti-human IgG and then sequentially incubated at
37 °C with receptor:Fc, FLAG ligands, biotinylated M2, and horserad-
ish peroxidase-coupled streptavidin. The binding of receptor:Fc was
also probed directly with a horseradish peroxidase-coupled rabbit anti-
human IgG polyclonal antibody.
Phospholipase C Treatment—Parental HEK-293 cells (2  105) and
stable transfectants expressing full-length mDcTRAILR1 or full-length
mDcTRAILR2L were incubated for 1 h at 37 °C in 100 l of DMEM 
10% FCS containing or not 0.05 unit of PI-PLC from B. thuringiensis.
After transfer on ice, cells were washed and sequentially stained with
50 l of FLAG-muTRAIL (100 ng/ml), 50 l of biotinylated M2 (1:500),
and 50 l of phycoerythrin-coupled streptavidin (1:500), and submitted
to FACS analysis.
Cytotoxicity Assay—For mTRAIL-induced Jurkat cell death, assays
were performed as described (22). Briefly, the TRAIL-sensitive Jurkat
cells were incubated for 16 h with the indicated amount of FLAG-
hTRAIL or FLAG-mTRAIL in the presence of 2 g/ml anti-FLAG M2
cross-linking antibody. In other experiments, cell death induced by a
fixed dose of FLAG-mTRAIL (50 ng/ml)  M2 antibody (2 g/ml)
was inhibited with the indicated amount of mDcTRAILR1:Fc,
mDcTRAILR2:Fc, or hTRAILR2:Fc. Cell viability was measured by the
phenazine methosulfate/3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay (Promega).
For 293T cell death induced by expression of various TNF receptor
family members, both adherent and floating cells, were collected 24–48
h post-transfection and stained with annexin V and 7-AAD (Pharmin-
gen) according to the manufacturer’s recommended protocol. Trans-
fected cells were identified as cells expressing GFP. Dead cells were
quantified as the percentage of GFP-positive cells that were also posi-
tive for 7-AAD staining.
Caspase and NFB Activity Assays—For caspase activity assay, 293T
cells (90-mm dish) were transfected with 7 g of indicated plasmids.
Cells were washed and harvested 24 h post-transfection and lysed in 70
l of lysis buffer (0.2% Nonidet P-40, 20 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 10% glycerol) for 10 min on ice. Caspase activity was determined
by loading 20 l (triplicate) of lysates in black 96-well plate followed by
addition of 100 l of DEVDase buffer (0.1% CHAPS, 2 mM MgCl2, 5 mM
of EGTA, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4,  21 l of 0.1 M
dithiothreitol 15 l of DEVD-AMC 5 mM in Me2SO). Fluorescence was
then measured (excitation 355 nm, emission 460 nm) at different time
points, and 5-h time point values are shown.
For NFB assay, 2  105 293T cells were plated in each well of
24-well plates overnight and then transfected with various amounts of
the indicated TNF receptor expressing vectors in triplicate together
with 40 ng of an NFB luciferase reporter construct. Luciferase activity
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was measured 24 h post-transfection using the LucLite luciferase re-
porter gene assay kit (PerkinElmer Life Sciences).
mTRAIL Binding Assay—293T cells were transfected with various
TNF receptor family members using the Polyfect Tranfection (Qiagen)
protocol. Briefly, cells were plated at 5  105 cells/well in 6-well plates
for 24 h and then cotransfected with 500 ng of a GFP expression
construct (AN050) and various concentrations of expression constructs
containing the individual TNF receptor family members. After 24–48 h,
cells were harvested and sequentially stained with FLAG-tagged
mTRAIL, an anti-FLAG M2 monoclonal antibody (Sigma, 1:2000), and
phycoerythrin-conjugated anti-murine IgG (Jackson ImmunoResearch,
1:200) each for 30 min at 4 °C. All cell samples were analyzed on the BD
Biosciences FACSCalibur.
To detect the binding of mTRAIL expressed on the cell surface, 293T
cells were transfected with either mock vector or full-length murine
TRAIL using LipofectAMINE 2000 (Invitrogen) according to the recom-
mended protocol. The cells were harvested 24 h later with 5 mM EDTA
in PBS and incubated for 1 h at room temperature with the following
murine receptor Fc fusion proteins diluted in FACS buffer:
DcTRAILR2L:Fc (10 g/ml), BCMA:Fc (10 g/ml), TRAILR2:Fc at (10
g/ml), and DcTRAILR2S:Fc (100 l of tissue culture supernatant).
After washing, the cells were incubated with phycoerythrin-labeled
goat anti-human IgG:Fc (Jackson ImmunoResearch) at 1:200 dilution
for 30 min at room temperature. After final washes, cells were resus-
pended in 1% paraformaldehyde/PBS and analyzed using the BD Bio-
sciences FACSCalibur.
Homology Modeling and Visualization—Models of mTRAIL trimer
(residues 125–291) complexed to a single subunit of mTNFRH3 (resi-
dues 41–148), mDcTRAILR1 (residues 52–160), and mDcTRAILR2
(residues 62–170) were built based on the crystal structure of human
TRAIL/DR5 (TRAILR2) complex (Protein Data Bank code 1D4V (24))
using the homology modeling module of the InsightII program (version
2000, Accelrys (25)). The alignment of the receptors used for modeling
is shown in Fig. 2A. Multiple models generated for each complex were
validated using ProsaII program (25), and the ones having lowest the z
scores were selected for further analysis. The models were visualized in
the MOLMOL program (26).
RESULTS
Identification of the Murine TNFRHs Locus on Chromosome
7F4—To identify potential new TNF receptor family members,
we used a TNFR signature profile (Prf:TNFR_NGFR_2 at www.
expasy.ch/cgi-bin/nicedoc.pl?PDOC00561) to search a data base
generated by the Swiss Institute of Bioinformatics that pre-
dicts proteins from the public genomic data bases. Our initial
screening resulted in one TNFR signature-containing hit from
the mouse genomic BAC clone RP23-6I17 (GenBankTM acces-
sion number AC068006). By using RT-PCR, we were able to
confirm that this TNF receptor-like gene was indeed expressed
(data not shown). Subsequent determination of its genomic
localization revealed a tight linkage to two potentially novel
TNF receptor homologous genes, Tnfrh1 and -2, predicted from
the genomic sequencing effort on the distal region of the mouse
chromosome 7, the murine syntenic region of the Beckwith-
Wiedemann syndrome (BWS) region in human ((27) Gen-
BankTM accession number of the full genomic locus, AJ276505).
Because the TNF receptor-like gene we identified is located to
the immediate 3 of the predicted Tnfrh1 and -2 genes, we
named the gene Tnfrh3. Based on the above information, we
hypothesized that there exists a previously unknown TNF re-
ceptor cluster on the distal region of mouse chromosome 7. We
then proceeded to obtain the full-length coding regions of all
three Tnfrh genes (see below), and we identified several BAC
clones (Resgen) containing the entire Tnfrhs locus. Upon ex-
tensive sequencing efforts, we concluded that, sandwiched be-
tween the obph1 and car1 genes, the three mTnfrh genes span
roughly 100 kb with no other apparent intervening genes,
based on analysis using GenScan (Fig. 1A). Because of our
functional data (see below), we propose to rename the first two
Tnfrh genes mDcTrailr1 and -r2.
Cloning, Sequence Analysis, and Expression Pattern of
mTNFRHs—Upon data base search, we found that a full-
length cDNA sequence containing the predicted cDNA se-
quence for mDcTrailr1 had been isolated previously and re-
ported in a patent filing (international publication number, WO
98/43998). We then employed two different approaches to ob-
tain the complete coding sequences for mDcTrailr2 and
mTnfrh3. For mTnfrh3, partial cDNA fragment amplified by
RT-PCR from total RNA prepared from the mouse ES cell line
E14 was used to probe a Stratagene mouse spleen cDNA phage
library, resulting in the isolation of a single mTnfrh3 full-
length cDNA clone (GenBankTM accession number AY165628).
For mDcTrailr2, the full coding region was obtained by a
combination of computer-assisted exon prediction and PCR
amplification from 1st strand DNA synthesized from NIH3T3
total RNA, which revealed the presence of two alternatively
spliced mDcTrailr2 variants (GenBankTM accession numbers
AY165626 and AY165627) (Fig. 1B).
As expected, each mTNFRH contains a signal peptide se-
quence at the N terminus followed by TNFR-like cysteine-
rich repeats, consistent with the typical type I membrane
protein topology observed in most TNFR family members
(Fig. 1B). The structures of their CRDs are remarkably sim-
ilar, with three tandem A1/B2 domains in both mDcTRAILR1
and mDcTRAILR2, whereas mTNFRH3 has two A1/B2 fol-
lowed by one A2/B2 domain (8) (Fig. 1C). The C-terminal por-
tions of the mTNFRHs, however, are surprisingly divergent.
Whereas mTNFRH3 contains a typical transmembrane do-
main (TM), the C terminus of mDcTRAILR1 instead exhibits
structural features of a GPI anchor addition signal (Fig. 1B)
(28). The two splice variants of mDcTRAILR2 also diverge in
their C termini. The cDNA spanning exons 1–7 contains a stop
codon within exon 6 and encodes a secreted soluble receptor
(mDcTRAILR2S), whereas the splice variant lacking exon 6
encodes a longer isoform (mDcTRAILR2L) containing a TM
region and a short intracellular domain. Finally, mDcTRAILR1
and -R2 are highly homologous with 71% identity at the amino
acid level (Fig. 1B), indicating a recent gene duplication event
at this locus.
We next examined the expression patterns of mTNFRHs in
both mouse tissues and cell lines. Based on Northern blot
analysis, the expression of mTnfrh3 is primarily restricted to
lymphoid tissues with a single 3-kb message detected in both
the thymus and spleen and at low but detectable levels in the
lung (Fig. 2A). The lymphoid-specific expression pattern of
mTnfrh3 was largely confirmed in Northern analysis of a num-
ber of murine cell lines, with its expression detected almost
exclusively in lymphoid cell lines, including both the T and B
lineages. The only noticeable exception is Colon 26, a colo-
rectal adenocarcinoma cell line that also expressed mTnfrh3
(Fig. 2B). The analysis of expression patterns of mDcTrailr1
and mDcTrailr2, however, is complicated by the extremely
high homology between these two genes. Although we could
confirm by RT-PCR that both mDcTrailr1 and -2 are indeed
expressed genes (data not shown), we were unable to distin-
guish their individual expression patterns by Northern analy-
sis due to cross-hybridization of the probe to both mRNAs.
Instead, the combined expression of mDcTrailr1 and mDc-
Trailr2, as determined by the presence of at least one of the
mRNA species, could be detected at low levels in all the mouse
tissues upon prolonged exposure (data not shown). In contrast,
the levels of expression were considerably higher in murine cell
lines, and various levels of combined expression can be detected
in most of mouse lines we have tested so far without obvious
patterns in the tissue/organ origins of the positive cell lines
(Fig. 2C).
Murine TNFRH1/DcTRAILR1 and TNFRH2/DcTRAILR2
Bind Specifically to the TNF Ligand TRAIL—The CRDs of
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TNF receptors not only provide the overall structural scaffold
but also determine their ligand binding specificity (8). In an
attempt to “deorphanize” mTNFRHs, we performed sequence
alignments of their CRD regions with those of the other known
TNF receptors. Our analysis revealed significant homologies
between mTNFRHs and TRAIL receptors, particularly in re-
gions of the TRAIL receptors that are involved in binding to
TRAIL (Fig. 1C), as suggested by the crystallographic studies
of the hTRAIL-hTRAILR2 complex (24, 29, 30).
To examine experimentally whether these novel TNF recep-
tors can indeed bind to the TNF ligand TRAIL, we first used an
ELISA-based screening assay that has been optimized for the
detection of interactions between TNF family ligands and re-
ceptors (22, 23). As shown in Fig. 3A, both mDcTRAILR1:Fc
and mDcTRAILR2L:Fc fusion proteins bound soluble mouse
TRAIL. Interestingly, mDcTRAILR2 also bound soluble human
TRAIL but to a lesser degree, whereas mDcTRAILR1 appeared
species-specific and did not interact at all with human TRAIL.
The interactions between mDcTRAILRs and soluble TRAIL
appeared highly specific because no other TNF ligand, includ-
FIG. 1. A, genomic structure of the new murine TNF receptor locus on chromosome 7. Three TNF receptor family genes, mTnfrh1/mDcTrailr1,
mTnfrh2/mDcTrailr2, and mTnfrh3, are clustered within 100 kb between Obph1 and Cars. The intron and intergenic sequences are shown at a
1:10 scale compared with exons. M, initiation codon for methionine; S, stop codon. There are two mRNA variants for mTnfrh2/mDcTrailr2 due to
alternative splicing of exon 6. B, alignment of the deduced amino acid sequences of mTNFRH1/mDcTRAILR1, mTNFRH2/mDcTRAILR1, and
mTNFRH3 based on sequence homology. Identical residues are dark-shaded, and residues with similar properties are light-shaded. Exon-intron
boundaries are indicated by crosses above the alignment. The open arrows indicates the predicted processing site of the signal peptide (SP). The
cysteine-rich domains (CRD1, -2, and -3), the glycosylphosphatidylinositol addition signal (GPI signal), and the transmembrane domains (TM) are
boxed. C, alignment of the CRD regions of mTNFRH1/mDcTRAILR1, mTNFRH2/mDcTRAILR1, mTNFRH3, and all other known TRAIL binding
TNF receptors. The positions of disulfide bonds are marked by squared brackets above (or below) the sequences. The dotted bracket indicates the
position of an additional disulfide bridge present in mTNFRH3 only. Black, gray, and white dots above the alignment indicate residues of
muDcTRAILR1, muDcTRAILR2, and hTRAILR2, respectively, that interact with TRAIL (in the crystal structure of hTRAILR2 complexed with
hTRAIL or in the model of muDcTRAILR1 and muDcTRAILR2 complexed with muTRAIL).
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ing the closely related RANKL, bound to mDcTRAILR1:Fc and
mDcTRAILR2L:Fc in this assay (Fig. 3A and data not shown).
Although the absolute binding affinities between these ligand/
receptor pairings have not been measured, our observations are
nonetheless suggestive of the possibility that mDcTRAILR1
and -R2 may compete effectively against muTRAILR2 for their
common ligand TRAIL. Surprisingly, mTNFRH3:Fc did not
bind to TRAIL, RANKL, or any other tested TNF ligand, de-
spite its sequence homology to mDcTRAILR1 and -R2 and
other TRAIL receptors (Fig. 3A). The ability of mDcTRAILR1
and -R2 to bind murine TRAIL was further examined by immu-
noprecipitation followed by Western blot. We found that, similar
to hTRAILR2:Fc and mTRAILR2:Fc, both mDcTRAILR1:Fc
and mDcTRAILR2L:Fc efficiently precipitated FLAG-tagged
murine TRAIL and again demonstrated the strict specificity
of mDcTRAILR1 for murine but not human TRAIL (Fig. 3B).
The ability of mDcTRAILR1 and -2 to bind TRAIL was fur-
ther demonstrated using a biological assay in which both
mDcTRAILR1:Fc and mDcTRALR2L:Fc inhibited significantly
mTRAIL-induced cytotoxicity in Jurkat cells (Fig. 3C).
We then confirmed the interactions between mTRAIL and
mDcTRAILR1 and -R2 by using full-length mDcTRAILR1 and
-R2 expressed on the cell surface (Fig. 3D). We found that
mTRAIL readily bound to 293T cells expressing mTRAILR2,
mDcTRAILR1, and mDcTRAILR2L. The failure of soluble
mTRAIL to bind 293T cells transfected with the mDcTRAILR2S-
expressing construct, as shown in Fig. 3D, is not surprising
because mDcTRAILR2S lacks the transmembrane domain and
does not express on the cell surface. To circumvent this problem,
we tested the ability of mDcTRAILR2S:Fc fusion protein to bind
293T cells expressing full-length mTRAIL on the surface. As
shown in Fig. 3E, both mDcTRAILR2S:Fc and mDcTRAILR2L:Fc
could bind surface mTRAIL. Based on these results, we conclude
that mDcTRAILR1, mDcTRAILR2L, and mDcTRAILR2S are
indeed previously unknown murine TRAIL receptors.
Murine TNFRH-1/DcTRAILR-1 and TNFRH-2/DcTRAILR-2
Are Putative Murine Decoy TRAIL Receptors—Whereas both
mDcTRAILR1 and mDcTRAILR2L appear to be surface recep-
tors for TRAIL, sequence analysis also suggests that they an-
chor in the cytoplasmic membrane by different mechanisms.
The C-terminal sequence of mDcTRAILR1 is a predicted glyco-
sylphosphatidylinositol (GPI) anchor addition signal, whereas
mDcTRAILR2L seems to contain a conventional transmembrane
domain with an extremely short cytoplasmic domain. In both
cases, the receptors do not seem to possess the ability, upon
ligand engagement, to trigger the various intracellular signal
transduction pathways involved in TRAIL-mediated cytotoxicity.
In contrast, mDcTRAILR2S is a secreted soluble receptor.
FIG. 2. A, tissue expression pattern of
mTNFRH3 by Northern blot (Ambion).
Relatively high expression of mTNFRH3
was detected in both thymus and spleen.
Low but detectable expression was seen
in the lung as well. B, expression pattern
of mTNFRH3 in various murine cell lines
by Northern blot. The expression of
mTNFRH3 can be detected in all lymph-
oid cell lines as well as the colon carci-
noma cell line Colon26. RNA from the
human B-cell line Raji was loaded as a
negative control. 20 g of RNA was loaded
for each cell line. C, combined expression
pattern of mTNFRH1/mDcTRAILR1 and
mTNFRH2/mDcTRAILR1 in murine cell
lines by Northern blot. Several mRNA
species can be detected in various cell
lines. RNA from the human B-cell line
Raji was loaded as a negative control. 20
g of RNA was loaded for each cell line.
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To demonstrate formally that mDcTRAILR1, but not
mDcTRAILR2L, is a GPI-anchored receptor, we employed a
well established method for assaying GPI anchorage of recep-
tors by measuring the sensitivity of surface receptors to phos-
phatidylinositol-specific phospholipase C (PI-PLC) (31). As ex-
pected, surface expression of mDcTRAILR2L, as determined by
FIG. 3. mDcTRAILR1 and -R2 are receptors for mTRAIL in both in vitro and cell-based assays. A, receptor and species specificity of
TRAIL and RANKL, as measured by ELISA. Receptor:Fc fusion proteins were allowed to interact with the indicated FLAG-tagged ligands at 37 °C.
Efficient coating of the receptor:Fc fusion proteins was assessed with a goat anti-human antibody. The ectodysplasin-A–ectodysplasin-A receptor
(EDA-EDAR) pair of ligand and receptor was used as a specificity control. B, receptor and species specificity of TRAIL, as measured by
coimmunoprecipitation. FLAG-tagged hTRAIL, muTRAIL, and hEDA were incubated with the indicated receptor:Fc fusion proteins. Following
immunoprecipitation (IP) with protein A-Sepharose, coimmunoprecipitated ligands were detected by anti-FLAG Western blot (WB) (lower panels).
The blot was subsequently reprobed with an anti-human Ig antibody (upper panels). C, inhibition of mTRAIL-induced Jurkat cytotoxicity by
mDcTRAILR1:Fc and R2:Fc. Left panel, titration of the cytotoxic activity of recombinant human and murine TRAIL on Jurkat cells. Right panel,
Jurkat cell were treated for 16 h with a constant amount of muTRAIL (50 ng/ml) and in the presence of the indicating amounts of hTRAILR2:Fc,
mDcTRAILR1:Fc, or mDcTRAILR2:Fc. Cell viability was measured by the phenazine methosulfate/3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. In this setting, untreated cells and cells treated with a lethal concentration of FasL gave
A490 nm of 1.4 and 0.27, respectively. D, FLAG-tagged soluble mTRAIL bound to 293T cells transiently transfected with full-length mTRAILR2,
mDcTRAILR1, or mDcTRAILR2L but not mDcTRAILR2S which presumably is not expressed on the cell surface. All cells were also cotransfected
with a GFP-expressing construct. The levels of binding, as measured by the percentage of GFP-positive cells that bind soluble mTRAIL by FACS
analysis, correlated with the amounts of DNAs transfected. E, FACS analysis of binding of various receptor:Fc fusion proteins to mTRAIL
expressed on the surface of 293T cells. 293T cells were transfected with a full-length mTRAIL-expressing construct and stained 24 h post-
transfection with the following receptor:Fc proteins: BCMA:Fc, mDcTRAILR1:Fc, and mDcTRAILR2L:Fc were all at 10 g/ml and 100 l of tissue
culture supernatant from 293T cells transfected with an mDcTRAILR2S:Fc-expressing construct.
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FIG. 4. A, PI-PLC sensitivity of mDcTRAILR1 and -R2. HEK-293 control cells and HEK-293 cells stably expressing mDcTRAILR1 or mDc-
TRAILR2 were treated with or without PI-PLC. Cells were subsequently stained with FLAG-tagged mTRAIL and analyzed by FACS. A control
without TRAIL staining is shown in the upper panel. B, mDcTRAILR1, mDcTRAILR2L, and mDcTRAILR2S do not induce apoptosis
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mTRAIL staining, was not altered following PI-PLC treatment,
indicating that mDcTRAILR2L anchors in the plasmic mem-
brane through its conventional TM region (Fig. 4A). On the
when other hand, an obvious decrease in mTRAIL staining
could be detected in mDcTRAILR1-expressing 293 cells treated
with PI-PLC (Fig. 4A), consistent with our hypothesis that
mDcTRAILR1 is a GPI-linked surface TRAIL receptor.
Signaling TRAIL receptors hTRAILR1, hTRAILR2, and
mTRAILR2 all contain the death domain motif in their cyto-
plasmic domains that is responsible for TRAIL-induced cyto-
toxicity, and the decoy receptors do not. Overexpression of
these death domain-containing receptors can induce apoptosis
in a number of cell lines such as 293 and NIH3T3, likely
through self-oligomerization of the receptors. We therefore
tested the effect of overexpression of mDcTRAILR1,
mDcTRAILR2L, and -R2S, on 293T survival. As demonstrated
in Fig. 4B, overexpression of death domain-containing recep-
tors TRAMP/DR3, hTRAILR2, or mTRAILR2, but not the hu-
man decoy receptors hTRAILR3 and -4, resulted in significant
cell death in 293T cell as measured by 7-AAD uptake. Tran-
sient transfection of mDcTRAILR1 and either the long or short
form of mDcTRAILR2 did not have any noticeable effect on the
survival of 293T cells, suggesting that mDcTRAILR1 and -R2
do not possess death-signaling capability. Consistent with this
hypothesis, overexpression of mDcTRAILR1 and -R2 did not
induce caspase activation that is characteristic of death recep-
tor signaling, as demonstrated in Fig. 4C.
Many TNF receptor family members can also activate the
NFB pathway, through direct or indirect association with the
TNF receptor-associated factor (TRAF) family members. Al-
though mDcTRAILR1 and -R2 do not seem to possess the
TRAF-binding motif according to sequence analysis, we none-
theless examined their ability to trigger indirectly NFB acti-
vation (Fig. 4D). As reported previously (21), transient trans-
fection of mTRAILR2 induced considerable NFB activation in
a dose-dependent manner as measured by cotransfection of an
NFB luciferase reporter construct. Overexpression of mDc-
TRAILR1 and both the long and short forms of mDcTRAILR2,
however, failed to induce NFB activity above that of the empty
vector control level, again in agreement with the notion that
both mTRAILR1 and -2 lack signaling capability and are likely
murine TRAIL decoy receptors.
Previous studies (32) have suggested that decoy receptors
could potentially inhibit ligand-induced cytotoxicity by directly
competing for the ligand and/or disrupting the proper assembly
of the signaling receptors. We have shown in Fig. 3C that apo-
ptosis of Jurkat cells triggered by mTRAIL can indeed be effi-
ciently blocked by both mDcTRAILR1:Fc and mDcTRALR2L:Fc,
supporting our hypothesis that mDcTRAILR1 and mDcTRAILR2
are likely decoy receptors that could function through ligand
competition. To examine the latter possibility, we took advan-
tage of the fact that receptor signaling induced by the over-
expression of mTRAILR2 mimics that triggered by engage-
ment of mTRAILR2 with TRAIL ligand. Our data clearly
indicate that the presence of mDcTRAILR1 or mDcTRAILR2L
has no apparent effect on 293T cell death induced by over-
expression of mTRAILR2, suggesting that neither
mDcTRAILR1 nor mDcTRAILR2L interferes with the proper
assembly of mTRAILR2 that is required for transducing the
apoptotic signaling (Fig. 4D).
DISCUSSION
In this study, we described the identification and character-
ization of a new TNF receptor locus where three TNF receptor-
like genes, Tnfrh1, -2 and -3, are located in tandem in the distal
region of mouse chromosome 7. The close proximity of these
three TNF receptor genes is not surprising as clusters of TNF
family ligands and receptors can be found in many parts of the
mammalian genome. For example, TNF, LT, and LT are all
tightly clustered within the major histocompatibility region on
chromosome 17 (mouse) and 6 (human). Similarly, two recently
identified TNF ligands Tweak and April are also closely linked
on human chromosome 17p13, whereas TL1A and CD30L are
on 9q32-33. On the receptor side, TNF-RI, LT-R, and CD27
are located at 12p13 (human), whereas TNFR-RII, HVEM,
CD30, and OX40 are clustered at 1p36 (human). Even more
strikingly, all four known human receptors for TRAIL are
found at 8p21-22. The presence of these clusters has led to the
suggestion that the expanding TNF family has evolved from a
limited number of ancestor molecules by means of gene dupli-
cation (1). Our identification of the Tnfrhs locus thus presents
yet another example of TNF family clustering. Perhaps more
interestingly, the Tnfrh1/mDcTrailr1 and Tnfrh2/mDcTrailr2
genes are extremely homologous with several stretches of
genomic sequences that are nearly identical, indicative of a
very recent duplicating event and providing by far the most
convincing evidence supporting the gene duplication theory.
We also demonstrated experimentally that mTNFRH1 and
-2, but not mTNFRH3, are receptors for TRAIL. Based on the
sequence characteristics and a number of in vitro studies, we
further propose that mTNFRH1 and -2 are in fact murine decoy
receptors for mTRAIL, and we renamed them mDcTRAILR1
and mDcTRAILR2, respectively. Although whether these two
murine TRAIL receptors function as decoy receptors in vivo
remains to be formally established, several lines of evidence
presented in this study, in particular their lack of both death
signaling and NFB activating capacity when overexpressed,
are consistent with this hypothesis. Interestingly, there are
considerable differences in the overall sequences between
mDcTRAILR1 and -R2 and the previously known human decoy
TRAIL receptors hTRAILR3 and -R4. Whereas the human re-
ceptors have the N1-A1-B2-A1-B2 cysteine module structure,
both mDcTRAILR1 and mDcTRAILR2 have the A1-B2 domain
instead of the N1 module. In addition, mDcTRAILR1 and -R2
do not possess either the membrane-proximal TAPE repeats
that are characteristic of the huTRAILR3 or the truncated
death domain present in huTRAILR4. These important differ-
ences suggest that, despite their apparent functional equiva-
lence, the murine and human TRAIL decoy receptors likely
have evolved independently.
overexpressed in 293T cells. 293T cells were cotransfected with either 2 or 1 g of indicated TNF receptor expression vectors and 0.5 g of GFP
expression vector. Cells were harvested 48 h later and analyzed by FACS for cell death based on annexin V and 7-AAD staining. The data shown
are representative of three separate experiments. C, transient transfection of mDcTRAILR1 and mDcTRAILR2L do not induce caspase activation
in 293T cells. 293T cells were transfected with indicated TNF receptor expression vectors. Cells were harvested 24 h later, and cellular caspase
activity was determined using the fluorogenic caspase substrate DEVD-AMC. The values shown are average of duplicate plates. D, mDcTRAILR1,
mDcTRAILR2L, and mDcTRAILR2S do not trigger NFB activation when overexpressed in 293T cells. 293T cells were cotransfected with indicated
amount of various TNF receptor expression vectors and 40 ng of an NFB luciferase reporter construct. Cells were harvested 24 h later for
luciferase activity assay, and the values shown are average of triplicate wells. E, cotransfection of mDcTRAILR1, mDcTRAILR2L, and
mDcTRAILR2S does not interfere with mTRAILR2-induced cell death in 293T cells. 293 cells were cotransfected with 1 g of mTRAILR2 expression
vector, 0.5 g of GFP expression vector, and either with 2, 1, or 0.5 g of indicated mDcTRAILRs. Cells were harvested 48 h later, and cell death
was analyzed as described under “Experimental Procedures.” The percentages of cell death are normalized against the absolute percentage of cell
death induced by transfection of mTRAILR2 alone.
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The divergence between mDcTRAILR1/R2 and hTRAILR3/R4
is also underscored by the potential differences in the mecha-
nisms by which they inhibit TRAIL cytotoxicity. It has been
reported previously (33) that, under physiological temperature,
the affinities of hTRAILR3 and -R4 for hTRAIL are about
50–100-fold lower than those between hTRAIL and its cognate
receptors hTRAILR1 and -R2. The observation suggests that
the hTRAILR3 and -R4 would be very poor competitors for
hTRAIL against hTRAILR1 and -R2, leading to the hypothesis
that the human decoy TRAIL receptors might inhibit hTRAIL-
induced cytotoxicity through some other mechanism(s), such as
by disrupting the proper assembly of the trimeric cognate re-
ceptors (33). In our studies, however, we found that coexpres-
sion of mDcTRAILR1 or -R2 has no effect on cell death induced
by mTRAILR2, arguing against such a scenario. It is therefore
possible that the murine decoy receptors may function by a
different mechanism than their human counterparts. Whether
they can do so through direct competition for the ligand re-
quires further investigation of the relative affinities of all mu-
rine TRAIL receptors for the TRAIL ligand.
The inability of mTNFRH3 to bind TRAIL is somewhat sur-
prising given its sequence homology to mDcTRAILR1 and -R2.
To understand the molecular basis of ligand selectivity exhib-
ited by these receptors, we performed molecular modeling of
the trimeric ligand/receptor interfaces between mTRAIL and
various mTNFRHs based on the crystal structure of human
TRAIL-TRAILR2 complex (Protein Data Bank code 1D4V) (24).
As expected from the significant sequence homology in the
CRD regions between hTRAILR2 and mDcTRAILR1 and -R2,
the predicted interactions between mTRAIL and mDcTRAILR1
or -R2 mirror those between hTRAIL and hTRAILR2 to a large
degree (Fig. 5A and data not shown).
Whereas the overall modeled structure of mTNFRH3 with
mTRAIL is similar to that of mTRAIL with mDcTRAILR1 or
-R2, we have identified two distinct features in the mTNFRH3
structure that may be responsible for its inability to bind
FIG. 5. A, portion of the modeled interface between mTRAIL (pink) and mDcTRAILR1 (green), mDcTRAILR2 (cyan), or mTNFRH-3 (blue).
Intramolecular disulfide bonds are labeled yellow and orange for the extra disulfide bond in mTNFRH3. The hypothetic interface between mTRAIL
and mTNFRH3 is likely destabilized due to the clustering of positively charged residues (Arg-86 and Arg-119 from mTNFRH3 and Arg-195 from
mTRAIL). B, comparative modeling of simulated ligand/receptor interfaces between the CRD2 regions of mDcTRAILR1 or -R2 and human versus
murine TRAIL. Potential interactions (both hydrophilic and hydrophobic) are marked in red. The strict species selectivity of mDcTRAILR1 for
murine but not human TRAIL is likely due to an essential electrostatic interaction between Asp-89 of mDcTRAILR1 and Lys-163 of muTRAIL that
is not present between mDcTRAILR1 and human TRAIL.
New Murine TNF Receptor Locus5452









mTRAIL. Based on the modeling, cysteines 111 and 116 are
positioned favorably to form a disulfide bond, resulting in the
A1-B2-A2-B2 CRD module arrangement, rather than A1-B2-
A1-B2 seen in mDcTRAILR1 or -R2. We also noticed that
mTNFRH3 has two arginines in positions 86 and 119 that are
not present in mDcTRAILR1 or -R2. When mapped on the
hypothetical model of the mTRAIL-mTNFRH3 complex (Fig.
5A), these residues were found to be located proximally to
Arg-195 of the mTRAIL, forming an unfavorable interaction
between three positively charged residues. Both mDcTRAILR1
and -R2, however, can form a salt bridge with Arg-195 of
mTRAIL via Asp-97 (mDcTRAILR1) or Asp-107 (mDcTRAILR2),
stabilizing the interaction. The bulky nature of Arg-119 in
mTNFRH3 also prevents its interaction with the side chain of
Tyr-247 (mTRAIL) and instead promotes its reorientation
toward Arg-86 (mTNFRH3) and Arg-195 (mTRAIL), result-
ing in the clustering of positive charges at the interface
between mTNFRH3 and mTRAIL that makes the formation
of a tight complex electrostatically unfavorable.
Our modeling further revealed possible structural basis for the
strict species selectivity exhibited by mDcTRAILR1, which binds
only mouse, but not human, TRAIL. Because mDcTRAILR2 is
highly homologous to mDcTRAILR1 yet binds both human and
mouse TRAIL, we closely examined the few residues involved
in ligand binding that are different between mDcTRAILR1 and
-R2, identifying a small cluster of such residues in the CRD2
regions of mDcTRAILR1 and -R2. As shown in Fig. 5B, it
appears that the interface between mDcTRAILR1 and mTRAIL
relies upon an important electrostatic interaction between
Asp-89 of mDcTRAIL1 and the Lys-163 of mTRAIL. This salt
bridge cannot occur with hTRAIL because it has the uncharged
Ser-159 at this corresponding position. Although mDcTRAILR2
has Ala-99 at this position, which also precludes an electro-
static interaction with either Lys-163 in mTRAIL or Ser-159 in
FIG. 6. Summary of the interactions of TRAIL and RANKL with their cognate receptors in the human and murine systems.
Cysteine-rich modules in the extracellular region of the receptors are schematized according to Bodmer et al. (8). hTRAILR1, hTRAILR2, and
mTRAILR2 contain an intracellular death domain (large gray boxes), and hTRAILR4 contains a truncated death domain. Consensus TRAF6-
binding sequences are shown as small gray boxes (in hRANK and mRANK) and consensus binding sequences for other TRAFs are shown as small
open boxes. hTRAILR3 and mDcTRAILR-1 are GPI-anchored receptors. The two splice variants of mdcTRAILR-2 (long and short) result in
membrane-bound or secreted receptors, respectively. mTNFRH3 interacts neither with TRAIL nor with RANKL but is related in sequence to
mdcTRAILR1 and -R2.
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hTRAIL, the interface between mDcTRAILR2 and either hu-
man or mouse TRAIL is stabilized by two additional interac-
tions that do not exist between mDcTRAILR1 and the TRAIL
ligand. The aspartic acid residue Asp-98 of the mDcTRAILR2,
but not the corresponding His-88 in mDcTRAILR1, can form a
salt bridge with Arg-158 of the hTRAIL and the corresponding
Arg-162 in mTRAIL. Similarly, a favorable hydrophobic inter-
action exists between the Tyr-225 of human TRAIL (Tyr-216 of
mouse TRAIL) and Ile-101 of mDcTRAILR2 but not the
charged corresponding residue Glu-98 in mDcTRAILR1.
The locus linkage of mDcTRAIL1 and -R2 to the murine
syntenic region of the human BWS locus is quite intriguing.
Beckwith-Wiedemann syndrome is a congenital overgrowth
syndrome whose pathogenesis has been linked to the abnormal
imprint regulation of several candidate genes located at chro-
mosome 11p15.5, a major imprinting cluster in the human
genome (34). Given the role of TRAIL in tumor surveillance, it
is tempting to speculate that the dysregulated expression of
decoy receptors for TRAIL as a result of loss of imprint could
potentially contribute to the failure in tumor suppression that
is often associated with BWS. Because the two known human
TRAIL decoy receptors are not located in the BWS region, the
potential presence in the BWS region of human homologs of
mDcTRAILR1 and -R2 that might be involved in the molecular
pathology of BWS needs to be investigated.
The TRAIL pathway has been a subject of intense research in
the past few years, largely due to the ability of TRAIL to
preferentially kill tumor cell lines in vitro and in vivo (35–37).
By using both TRAIL-deficient mice and a TRAIL-neutralizing
antibody, more recent studies (38–40) have established that
the TRAIL-mediated cytotoxicity pathway is critical for tumor
surveillance by the immune system in vivo. Given the presence
of both signaling and decoy receptors for TRAIL, it has been
hypothesized that the ability of TRAIL to selectively target
certain tumor cells is determined by the relative expression
levels of these antagonizing receptors (14, 41). Repeated ef-
forts, however, have failed to establish a clear link between
TRAIL responsiveness and the expression pattern of various
TRAIL receptors in many normal and tumor cells (39, 42). As a
result, the in vivo function of the decoy TRAIL receptors and
their relevance to the tumor-suppressing activity of TRAIL
demonstrated in TRAIL-deficient mice remains unclear. In this
study, we report the identification of putative decoy receptors
for TRAIL in the mouse. Our discovery thus reveals that a
comparably complex set of interactions between TRAIL ligand
and its cognate as well as decoy receptors exists in both human
and mouse (Fig. 6). The identification of these mDcTRAILR1
and -R2 will also make it possible to generate mice deficient in
these decoy receptors, thus allowing definitive analysis of their
possible in vivo contribution in modulating the sensitivity of
different cell types to TRAIL.
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